Charles River Laboratories International, Inc. (CRL) earnings
CRL earnings moved a median of -1.42% by the close. Quarterly and annual CRL reports and results, each read against the price at its own news timestamp. Back to the CRL overview →
34 measured CRL earnings events.
Where these CRL earnings landedvs 34 measured CRL earnings reactions
| Middle 50% of CRL earnings reactions | -2.66% to +0.74% |
|---|---|
| Median reaction (to close) | -1.42% |
| Measured reactions | 34 |
Point-in-time · zero look-ahead
Half of the 34 CRL earnings events with a measured close landed between -2.66% and +0.74%; 29% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call | Press release | +0.27% | +0.79% | |
| Charles River Laboratories Announces Second-Quarter 2026 Results | Press release | -1.31% | -0.87% | |
| Form 10-Q CHARLES RIVER LABORATORI For: Jun 27 | SEC filing · Form 10-Q | -1.31% | -0.87% | |
| Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call | Press release | +0.00% | -1.76% | |
| Charles River Laboratories Announces First-Quarter 2026 Results | Press release | +1.21% | -3.41% | |
| Form 10-Q CHARLES RIVER LABORATORI For: Mar 28 | SEC filing · Form 10-Q | -0.68% | -2.71% | |
| Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call | Press release | +1.64% | -1.40% | |
| Form 10-K CHARLES RIVER LABORATORI For: Dec 27 | SEC filing · Form 10-K | +5.07% | +7.62% | |
| Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call | Press release | -0.63% | -1.91% | |
| Charles River Laboratories Announces Third-Quarter 2025 Results | Press release | +2.90% | +2.70% | |
| Form 10-Q CHARLES RIVER LABORATORI For: Sep 27 | SEC filing · Form 10-Q | +2.90% | +2.70% | |
| Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call | Press release | +0.03% | +1.01% | |
| Charles River Laboratories Announces Second-Quarter 2025 Results | Press release | -0.12% | -4.36% | |
| Form 10-Q CHARLES RIVER LABORATORI For: Jun 28 | SEC filing · Form 10-Q | -0.12% | -4.36% | |
| Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call | Press release | -1.02% | -2.92% | |
| Charles River Laboratories Announces First-Quarter 2025 Results | Press release | -0.17% | -2.16% | |
| Form 10-Q CHARLES RIVER LABORATORI For: Mar 29 | SEC filing · Form 10-Q | -0.17% | -2.16% | |
| Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call | Press release | +1.37% | -1.45% | |
| Form 10-K CHARLES RIVER LABORATORI For: Dec 28 | SEC filing · Form 10-K | -0.18% | +3.59% | |
| Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call | Press release | -1.23% | -0.83% | |
| Charles River Laboratories Announces Third-Quarter 2024 Results | Press release | -4.16% | -3.69% | |
| Form 10-Q CHARLES RIVER LABORATORI For: Sep 28 | SEC filing · Form 10-Q | -4.16% | -3.69% | |
| Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call | Press release | -0.15% | -0.15% | |
| Charles River Laboratories Announces Second-Quarter 2024 Results | Press release | +5.62% | +3.57% | |
| Form 10-Q CHARLES RIVER LABORATORI For: Jun 29 | SEC filing · Form 10-Q | +5.62% | +3.57% | |
| Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call | Press release | +0.60% | -1.50% | |
| Charles River Laboratories Announces First-Quarter 2024 Results | Press release | -2.87% | -2.50% | |
| Form 10-Q CHARLES RIVER LABORATORI For: Mar 30 | SEC filing · Form 10-Q | -2.87% | -2.50% | |
| Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call | Press release | +0.50% | -1.12% | |
| Form 10-K CHARLES RIVER LABORATORI For: Dec 30 | SEC filing · Form 10-K | -0.38% | +8.05% | |
| Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call | Press release | -0.61% | -1.36% | |
| Charles River Laboratories Announces Third-Quarter 2023 Results | Press release | -4.42% | -3.62% | |
| Form 10-Q CHARLES RIVER LABORATORI For: Sep 30 | SEC filing · Form 10-Q | -4.42% | -3.62% | |
| Charles River Laboratories Schedules Third-Quarter 2023 Earnings Release and Conference Call | Press release | -0.10% | +0.58% |
Keep exploring
More CRL: analyst actions → · SEC filings → · CRL overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CATASYS (CATS) | 434 | 0.00% | 41% |
| Cytocom Inc. (CBLI) | 434 | 0.00% | 40% |
| Nymox Pharmaceutical Corporation (NYMX) | 433 | 0.00% | 48% |
| IMMUNE DESIGN CORP COMMON STOCK (IMDZ) | 432 | -0.12% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.